Advances in understanding of idiopathic pulmonary fibrosis

Chinese Medical Journal

Volumn 122, Issue 7, 2009, Pages 844-857

  Wang, Zeng Li ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Adrenal cortex hormones; Idiopathic pulmonary fibrosis; Immunosuppressive agents

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BOSENTAN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GAMMA INTERFERON; GAMMA1B INTERFERON; GLUCOCORTICOID; INTERLEUKIN 8; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PENICILLAMINE; PIRFENIDONE; PLACEBO; PREDNISOLONE; PREDNISONE; REVALIO; SILDENAFIL; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ALLERGIC PNEUMONITIS; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARDIOPULMONARY EXERCISE TEST; CLINICAL TRIAL; CUSHING SYNDROME; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE TOLERANCE; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG BIOPSY; LUNG FIBROSIS; LUNG LAVAGE; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

ADRENAL CORTEX HORMONES; ANIMALS; ANTICOAGULANTS; ANTIOXIDANTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOLOGIC FACTORS; LUNG TRANSPLANTATION; PYRIDONES;

EID: 68249159428     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.07.016     Document Type: Article

References (90)

1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respire Crit Care Med 2006; 174: 810-816.
2. Olsen AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Case Med 2007; 176: 277-284.
3. Crystal RG, Bitteoman PB, Mossman B, Schwarz MI, Chinese Medical Journal 2009;122(7):844-857 855 Sheppard D, Almasy L, et al. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respire Crit Care Med 2002; 166: 236-246.
4. Moss M. Clinical year in review II. Interstitial lung disease, sepsis, pubnonary infections, and sleep medicine. Proc Am Thorax Soc 2007; 4: 482-488.
5. Noble PW, Homer RJ. Back to the future historical perspective on the pathogenesis of idiopathic palmary fibrosis. Am J Respire Cell Mol Biol 2005; 33: 113-120.
6. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis. The myofrroblast in focus. Chest 2007; 132: 1311-1312.
7. Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004; 55: 395-417.
8. Huminghake GW, Schwarz MI. Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis. Proc Am Thorax Soc 2007; 4: 449-452.
9. Eickelberg O, Panskg A, Koebler E, Bihl M, Tamm M, Hildebrand P, et al. Molecular mechanisms of TGF-α antagonism by interferon γ and cyclosporine A in lung fibroblasts. FASEB J 2001; 15: 797-806.
10. Selman M, Thanmickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP 3rd. Idiopathic pulmonary fibrosis. Pathogenesis and therapeutic approaches. Drug 2004; 64: 405-430.
11. Myllärniemi M, Lindhdm P, Ryynämem MJ, Kliment CR, Salmenkivi K, Keski-Oja J, et al. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Cate Med 2008; 177: 321-329.
12. Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z, et al. Inhibition of integrin alpha(V)β6, an activator of latent transforming growth factor-β prevents radiation-induced lung fibrosis. Am J Respir Crit Cre Med 2008; 177: 82-90.
13. Antoniou KM, Hansell DM, Rubens MB, Marton K, Desci SR, Siafakas NM, et al. Idiopathic pulmonary fibrosis outcome in relation to smoking status. Am J Respire Crit Care Med 2008; 177: 190-194.
14. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorax Soc 2006; 3: 364-372.
15. Muro AF, Moretti FA, Moore BB, Yan M, Atrasz RG, Wilke CA, et al. An essential role for fibronection extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 638-645.
16. Renzoni EA, Walsh DA, Salmon M, Wells AV, Sestioni P, Nichalson AG, et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003; 167: 438-443.
17. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary and pulmmary hypertension connecting the dots. Am J Respir Crit Care Med 2007; 175: 875-882.
18. Tzouvelekis A, Harokopos V, Paparountas T, Oikonomou N, Chatziioammou A, Vilaras G, et al. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1α in disease pathogenesis. Am J Respir Crit Care Med 2007; 176: 1108-1119.
19. Ye Q, Dalavanga Y, Poulakir N, Sixt SV, Guzman J, Costabel U. Decreased expression of haem oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis. Eur Respir J 2008; 31: 1031-1036.
20. Mora AL, Torrez-Gonzalez T, Rojas M, Corredor C, Ritzenthaler J, Xu J, et al. Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respire Cell Mol Biol 2006; 35: 466-473.
21. Brass DM, Tomfohr J, Yang IV, Schwartz DA. Using mouse genomics to understand idiopathic interstitial fibrosis. Proc Am Thorac Soc 2007; 4: 92-100.
22. Caminati SH. Idiopathic pulmonary fibrosis. Allergy 2005; 60: 421-435.
23. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, et al. Idiopathic pulmonary fibrosis. Prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006; 174: 803-809.
24. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:659-664.
25. Hamada K, Nagai S, Tanoka S, Handa T, Shigemasu M, Nagao T, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131:650-656.
26. Costabel V. Ask the expert-diffuse interstitial lung disease. Breathe 2007; 4: 165-172.
27. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133: 226-232.
28. Veeraraghavan S, Lats PI, Wells AV. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003; 22: 239-244.
29. Tabuena RP, Nagai S, Tsutsumi T. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese patients. Respiration 2005; 72: 490-498.
30. Martinez FJ, Safrin S, Weycter D, Strko KM, Bradford WZ, King Jr TE, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Int Med 2005; 142: 963-967.
31. Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest 2007: 132: 637-650.
32. Aziz ZA, Wells AU, Bateman ED, Copley SJ, Desai SR, Grutters JC, et al. Interstitial lung disease: effects of thin-section CT on clinical decision making. Radiology 2006; 238: 725-733.
33. Zisman DA, Karlamangla AS, Ross DJ, Keanc MP, Bdperia JA, Saggar R, et al. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007; 132: 773-779.
34. Gotway MB, Freemar MM, King TE Jr. Challenges in pulmonary fibrosis. 1: Use of high resdution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneamonius. Thorax 2007; 62: 546-553.
35. Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, et al. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J 2008; 31: 585-591.
36. Diette GB, Scatarige JC, Haponik EF, Merriman B, Fishman EK. Do high-resolution CT findings of usual interstitial pneumonitis obviate lung biopsy? Views of pulmonologists. Respiration 2005; 72: 134-141.
37. Sumikawa H, Johkoh T, Colby TV, Ichikado K, Suga M, Taniguchi H, et al. Computed tomography findings in pathological usual interstitial pneumonia. Relationship to survival. Am J Respir Crit Care Med 2008; 177: 433-439.
38. Flatherty KP. High-resotution computed tomograph and the many faces of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:367-368.
39. Swigris JJ, Gould MK, Wilson SR. Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest 2005; 127: 284-294.
40. De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J 2001; 17: 954-961.
41. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med 2005; 99: 408-414.
42. Watter N, Collard HR, King TE. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3: 330-338.
43. Williams TJ, Wilson JM. Challenges in pulmonary fibrosis: 7 - Novel therapies and lung transplantation. Thorax 2008; 63: 277-284.
44. Stricter RM. Pathogenesis and natural history of usual interstitial pneumonia. The whole story or the last chapter of a long novel. Chest 2005; 128 (5 Suppl 1): 526-532.
45. Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005; 26: 693-702.
46. duBois RM. Therapeutic options and management of pulmonary fibrosis: old and new. Brethe 2006; 2: 351-353.
47. Selman M, King TF, Pardo A. Idiopathic pulmonary fibrosis prevailing and evolving hypothesis about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151.
48. Raghu G, Depaso WJ, Caim K. Azathiopurine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, drubleblind randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296.
49. Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curran- Everett D, King TE Jr, et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004; 125: 2169-2174.
50. Pereira CA, Malheiros T, Coletta EM, Ferreira RG, Rubin AS, Otta JS, et al. Survival in idiopathic pulmonary fibrosis-cytotrxic agents compared to corticosteroids. Respir Med 2006; 100: 340-347.
51. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter prospective, randomized double-blind placebo-controlled trial of corticosteroids and intravenous cyclophos phamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-3970.
52. Tashikim DP, Elahoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effents of 1-year treatment with cyclophosphamide on outcomes at 2 years in sclerodema lung disease. Am J Respir Crit Cave Med 2007; 76: 1026-1034.
53. Boster A, Edan G, Frogman E, Javed A, Stuvue O, Tselis A, et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neural 2008; 7: 173-183.
54. Johnson WC, Raghu G. Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures. Eur Respir J 2005; 26: 755-758.
55. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane database of systematic reviews. 2006, Issue 3.
56. Raghu G. Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches. Eur Respir J 2006; 28: 463-465.
57. Blesa S, Cortijo J, Mata M, Serrano A, Closa D, Santangelo F, et al. Oral N-autylcysteine attenuates the rat pulmonary inflammatory response to antigen. Eur Respir J 2003; 21: 394-400.
58. Demedts M, Behr J, Buhl R, Constable V, Delkhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
59. Wells AU. Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled. Eur Respir J 2006; 27: 664-666.
60. Humminghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2285-2287.
61. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respire Crit Care Med 1999; 159: 1061-1069.
62. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
63. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002; 41: 1118-1123.
64. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabl M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.
65. Center D. Taking the "idio" out of idiopathic pulmonary fibrosis. Am J Respire Crit Care Med 2007; 175: 1101-1103.
66. Ziesche R, Hofbauer E, Wittmannk, Pietkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-1269.
67. Antoniou KM, Nicholson AG, Dimadi M, Malagari K, Latsi P, Rapti A, et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 2006; 28: 494-504.
68. King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, et al. Analyses of efficacy end points in a controlled trial of interferon-?1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-177.
69. Raghu G, Brown KK, Braford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. New Engl J Med 2004; 350: 125-133.
70. Honore I, Nunes H, Groussard O, Kambouchner M, Chambellan A, Aubier M, et al. Acute respiratory failure after interferon-γ therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med 2003; 167: 953-957.
71. Selman M. A dark side of interferon-γ in the treatment of idiopathic pulmonary fibrosis? Am J Respir Crit Care Med 2003; 167: 945-947.
72. Channick RN, Silbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 625-675.
73. Rubin IJ, Badesch DB, Barst RJ. Bosentan therapy for pulmonary arterial hypertansion. N Engl J Med 2002; 346: 896-903.
74. Günther A, Enke B, Markart P, Hammeri P, Morr H, Behr J, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respire J 2007; 29: 713-719.
75. King TE, Behr J, Brown KK, duBois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
76. Opitz CF, Ewert R, Kirch W, Pittrew D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 2008; 29: 1936-1948.
77. Mackay LS, Anderson RL, Parry G, Lordan J, Corris PA, Fisher AJ. Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation. Thorax 2007; 62: 1069-1073.
78. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King ET, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-643.
79. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27: 143-150.
80. Hyzy R, Huang S, Myors J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007; 132: 1652-1658.
81. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KI, Chaswalit N, Deaker PA, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399.
82. Fell CD, Martinez FJ. The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. Chest 2007; 131: 641-643.
83. Zisman DA, Karlamagla AS, Kawut SM, Shlobin OA, Saggar R, Ross DJ, et al. Validation of a mothod to screen for pulmonary hypertension in advanced idiopathic pabmonary fibrosis. Chest 2008; 133: 640-645.
84. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
85. Patel NM, Lederer DJ, Barczuk AC, Kawat SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132: 998-1006.
86. Collard HR, Angstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131: 897-899.
87. Klinger IR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in-patients with pulmonary arterial hypertension. Chest 2006; 129: 417-425.
88. Peivert T, Damets CE, Becker TJ, Meyer KC, Ryu JH. American College of Chest Physicians (ACCP) survey on the diagnosis and therapy of idiopathic pulmonary fibrosis (IPF). Chest 2007; 132 Suppl: S585.
89. Fadini GP, Schiavon M, Rea F, Avogaro C. Depletion of endothelial progenitor cells may link pulmonary fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2007; 176: 724-725.
90. Ask K, Martin GE, Kolb M, Gauldie J. Targeting genes for treatment in idiopathic pulmonary fibrosis: challenge and opportunities, promises and pitfalls. Proc Am Thoras Soc 2006; 5: 389-393.